Stockhead5h
Crucible: This rare blood disease tackler plans to hit investors with its best shot
The myelofibrosis drug landscape has become more crowded since Syntara decided to focus on the disease in 2020, but the ...
Dr Boreham’s Crucible: This rare blood disease tackler aims to hit investors with its best shot
While the myelofibrosis drug landscape has become more crowded since Syntara (then Pharmaxis) decided to focus on that ...